10-K: Alterola Biotech Files 10-K Annual Report, Cites Going Concern Doubts Amidst Development Efforts

Alterola Biotech's annual report reveals ongoing financial challenges and a lack of revenue, while highlighting its focus on cannabinoid-based pharmaceutical development.

Summary

• Alterola Biotech, a pharmaceutical company focused on cannabinoid-based medicines, filed its annual report on Form 10-K for the fiscal year ended March 31, 2024.
• The company has generated no revenue and has an accumulated deficit of $12,406,419, raising substantial doubt about its ability to continue as a going concern.
• Alterola is pursuing three main areas: development of regulated pharmaceuticals and food products, low-cost production of active pharmaceutical ingredients (API), and formulation and drug delivery technologies.
• The company acquired intellectual property related to novel compounds and production methods through acquisitions of ABTI Pharma, Phytotherapeutix Ltd, Ferven Ltd, and Alinova Biosciences Ltd.
• Alterola faces significant competition in the pharmaceutical and non-pharmaceutical sectors, with many competitors having greater financial and technical resources.
• The company is subject to extensive regulations in the U.S., Europe, and Japan, including those related to controlled substances.
• The regulatory approval process for new medicines is lengthy and costly, with no guarantee of success.
• Alterola anticipates needing to raise $25,000,000 for operations in the next 12 months and $81,000,000 in total for initial clinical development programs.
• The company's internal controls over financial reporting were deemed ineffective due to inadequate segregation of duties and insufficient written policies.
• The company's common stock is currently considered a penny stock, which may make it difficult for investors to sell their shares.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a lack of revenue, substantial accumulated deficit, and doubts about the company's ability to continue as a going concern. While there are positive aspects such as the company's intellectual property portfolio and management experience, the overall tone is negative due to the financial instability and operational risks.

Positives

• Alterola has acquired a portfolio of intellectual property related to cannabinoid-based medicines and production methods.
• The company has a management team with extensive experience in the cannabinoid sector.
• Alterola is pursuing multiple strategies for drug development, including botanical, chemical synthesis, and biosynthetic methodologies.
• The company has established a fully operational US$ and a sterling bank account in the United Kingdom with the HSBC Group.
• The company has a third-party consultant to assist with its cybersecurity risk management framework.

Negatives

• Alterola has generated no revenue and has a significant accumulated deficit.
• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's common stock is currently considered a penny stock, which may make it difficult for investors to sell their shares.
• The company is dependent on outside financing for continuation of its operations.
• The company has a limited operating history, making it difficult to evaluate its prospects.
• The company's operating results may fluctuate due to various factors, some of which are beyond its control.
• The company has not yet achieved a profit and may not achieve a profit in the near future, if at all.
• The company is dependent on the continued services of its key staff and may face challenges in retaining and attracting qualified personnel.
• The company has not obtained directors and officers liability (D&O) insurance.

Risks

• The company's business and future operations may be adversely affected by epidemics and pandemics, such as the recent COVID-19 outbreak.
• There are doubts about the company's ability to continue as a going concern due to its lack of revenue and accumulated deficit.
• The company is dependent on outside financing for continuation of its operations, and there is no assurance that such financing will be available.
• The company's operating results may fluctuate due to various factors, some of which are beyond its control.
• The company may not be able to retain key staff or attract qualified personnel.
• The company's lack of adequate D&O insurance may make it difficult to retain and attract talented and skilled directors and officers.
• The company has an outstanding material weakness related to its internal controls over financial reporting.
• The company will likely conduct further offerings of its equity securities in the future, which may dilute existing shareholders' interests.
• The company's common stock price may be volatile and could fluctuate widely in price.
• The company's existing stockholders may experience significant dilution from the sale of common stock pursuant to the EMC2 Purchase Agreement.
• The company may become involved in securities class action litigation.
• The company's common stock is currently deemed a penny stock, which makes it more difficult for investors to sell their shares.
• The company has made and expects to continue to engage in acquisition activities that could disrupt its operations and harm its operating results.
• The company's future success will largely depend on the success of its drug candidates, which development will require significant capital resources and years of preclinical and clinical development effort.
• The company's drug development projects, if approved, may be unable to achieve the expected market acceptance.
• Results of preclinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
• The regulatory approval processes with the FDA, the EMA and other comparable foreign regulatory authorities is lengthy and inherently unpredictable.
• The company's drug candidates may become subject to controlled substance laws and regulations in the U.S.
• Clinical trials of cannabinoid-based drug candidates are novel with very limited or non-existing history.
• The company faces a potentially highly competitive market.
• The company's failure to comply with existing and potential future laws and regulations relating to drug development could harm its plan of operations.
• The company's failure to be able to out-license some or all of its pipeline drug candidates could harm its plan of operations.
• The company's failure to be able to enter Research and Development (R & D) Collaboration Agreements or Joint Venture (JV) Agreements for some or all of its pipeline drug candidates could harm its plan of operations.
• The introduction of new businesses, products, services, and technologies, the company's activities in certain jurisdictions, or other actions it takes may subject it to additional laws and regulations.
• The company could be subject to litigation, allegations or other legal claims.

Future Outlook

The company anticipates needing to raise $25,000,000 for operations in the next 12 months and $81,000,000 in total for initial clinical development programs. The company expects that its operational expenses will increase significantly for the balance of the fiscal year ended March 31, 2025 and beyond.

Management Comments

• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• Management plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures.

Industry Context

The cannabinoid-based pharmaceutical sector is highly competitive, with many companies developing similar products. Alterola faces competition from both large multinational pharmaceutical companies and smaller biotechnology companies. The regulatory landscape is complex and varies across different regions, requiring significant resources to navigate.

Comparison to Industry Standards

• Many early-stage biotechnology companies, particularly those focused on novel therapeutics like cannabinoids, face similar challenges with high R&D costs, regulatory hurdles, and the need for substantial capital raises.
• The lack of revenue and significant accumulated deficit are not uncommon for companies in this stage of development, but the explicit mention of 'going concern' issues is a serious concern.
• The company's reliance on external financing is typical for pre-revenue biotech firms, but the specific amount needed ($25 million in 12 months, $81 million total) highlights the scale of the challenge.
• The identified material weaknesses in internal controls are a common issue for smaller reporting companies, but they need to be addressed to ensure financial reporting reliability.
• Compared to companies like GW Pharmaceuticals (now Jazz Pharmaceuticals), which successfully developed and commercialized cannabinoid-based drugs, Alterola is at a much earlier stage and faces significant hurdles to achieve similar success.
• The company's focus on low-cost API production and advanced drug delivery systems is a strategic move to differentiate itself in a competitive market, but it remains to be seen if these strategies will be successful.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The company leases office space from Equipped 4 Properties Limited at an independently determined commercial rate.
• During the period ended March 31, 2023, Phytotherapeutix Holdings Limited, TPR Global Limited, Equipped 4 Holdings Ltd and Equipped 4 IP Limited, and Opes Medical Holdings Limited and Colin Stotts Tim Rogers and Dominic Schillers Directors Loan Accounts made advances to the company to fund operating expenses in the amount of $1,260,434.
• On October 16, 2023, TPR Global Limited, Equipped 4 Holdings Limited and Phytotherapeutix Holdings Ltd converted a total of $2.35m USD of debt in the Company into common shares at a price of $0.004 per share.
• As part of an agreement dated March 12, 2024, Bright Green Corporation agreed to return 83,226,814 shares of common stock of Alterola to the three shareholders (Equipped4 Holdings Limited (Equipped), Phytotherapeutix Holdings Ltd. (Phyto), and TPR Global Limited (TPR)) who had initially sold the shares to Bright Green.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution from future equity offerings.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers and suppliers may be affected by the company's ability to continue operations and fulfill its obligations.
• Creditors face the risk of non-payment due to the company's going concern issues.

Next Steps

• The company plans to seek additional financing through private or public offerings.
• The company intends to continue developing its pipeline of cannabinoid-based drug candidates.
• The company plans to address the identified material weaknesses in its internal control over financial reporting.
• The company may consider out-licensing some of its assets to other pharmaceutical or biotechnology companies.
• The company may enter into Research and Development Collaboration Agreements or Joint Venture Agreements with other companies.

Key Dates

Keywords

cannabinoid, pharmaceutical, drug development, API, clinical trials, regulatory approval, biotechnology, intellectual property, controlled substances, FDA, EMA, going concern, penny stock, internal controls, financial reporting